ContraceptionHGOPYNCT03733678
A Randomized-Controlled Trial to Increase the Uptake of LARCs in Cameroon
A study testing Price discounts for SARCs, Price discounts for LARCs and Sequential vs. simultaneous recommendations in people with Contraception and Contraception Behavior, run by World Bank at 1 site in Cameroon.
Trial summary
Cameroon exhibits a high and non-decreasing level of maternal mortality (roughly 600 per 100,000 live births), partially related to its relatively high total fertility rate (roughly 4.6). Read more about this study
- Who is it for?
- Ages 10 to 49 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Contraception, Contraception Behavior, Contraceptive Usage
- What is being tested?
- Price discounts for SARCs, Price discounts for LARCs and Sequential vs. simultaneous recommendations
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,500 participants
- Where
- 1 siteCameroon
- Study dates
- 23 Mar 2021to 31 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 49 years
- Women only
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Female
- Ages 10-49
- Presenting at HGOPY seeking FP counseling/services
- HGOPY clients referred to the family planning unit for consultation
Who cannot join
- No exclusion criteria
Trial locations and contacts
1 site in 1 country.
Cameroon1 site
Hôpital gynéco-obstétrique et pédiatrique de Yaoundé (HGOPY)
Yaoundé
About this study
Official title: A Sequential and Adaptive Experiment to Increase the Uptake of Long-acting Reversible Contraceptives in Cameroon
Cameroon exhibits a high and non-decreasing level of maternal mortality (roughly 600 per 100,000 live births), partially related to its relatively high total fertility rate (roughly 4.6). Survey evidence furthermore suggests that a significant fraction of these pregnancies is unwanted or considered mistimed by the mother, especially among females aged 15-19. Despite this, the rate of utilization of family planning (FP) is low: e.g. only 48% of sexually active unmarried women use any form of (modern) contraception, or MC, and even then, it is primarily condoms. The use of LARCs (long-acting reversible contraceptives, i.e. the IUD and implant) is less than 1% according to the most recent Demographic Health Survey.
The study investigators propose to use an integrated behavioral science approach to increase the take-up of both SARCs (short-acting reversible contraceptives, i.e. the pill and injectable) and especially LARCs among reproductive-age females in Cameroon, including adolescents who may be unmarried and/or nulliparous. In addition to decreasing maternal mortality and undesired pregnancies, indirect effects for the community will include: increased welfare from reduced side effects that arise due to current one-size-fits-all FP counseling; healthier children due to improved birth spacing; and increased human capital formation both for children and for young (often school-aged) potential mothers.
The study investigators propose to conduct the study at HGOPY for a duration of 12 months. The study investigators will provide tablets to each of five nurses that conduct FP counseling to participants at the hospital. The tablets contain a counseling "app" (or decision-support tool or a job-aid) that was jointly developed by professionals from HGOPY, the World Bank, and the Ministry of Health. The study investigators propose an individually-randomized experiment, where the participants will be offered randomly varying discounts for the modern contraceptive methods they wish to adopt. The study investigators also propose to experiment with certain aspects of the "app" to improve its effectiveness - both for the participant and for the nurse. More details on the experimental design are provided below.
- Conditions
- Contraception, Contraception Behavior, Contraceptive Usage, Contraceptive Method Switching
- Being tested
- Price discounts for SARCs, Price discounts for LARCs, Sequential vs. simultaneous recommendations
- Keywords
- adolescent sexual and reproductive health, maternal mortality, teen pregnancy, LARCs, family planning counseling
- Medical subject headings
- Contraception Behavior, Maternal Death
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Price discounts for SARCsBehavioural
SARCs are offered free to the client
Price discounts for LARCsBehavioural
LARCs are offered at lower prices to the client
Sequential vs. simultaneous recommendationsBehavioural
Top ranked methods are presented to the client sequentially or simultaneously
| Study group | Role | What they receive |
|---|---|---|
| Free SARC, Free LARC, Recommendation | Experimental | Free SARC, Free LARC, Sequential recommendation Receives: Behavioral: Price discounts for SARCs; Behavioral: Price discounts for LARCs |
| Free SARC, LARC=500, Recommendation | Experimental | Free SARC, LARC=500 CFA, Sequential recommendation Receives: Behavioral: Price discounts for SARCs; Behavioral: Price discounts for LARCs |
| Free SARC, LARC=1000, Recommendation | Experimental | Free SARC, LARC=1000 CFA, Sequential recommendation Receives: Behavioral: Price discounts for SARCs; Behavioral: Price discounts for LARCs |
| Free SARC, LARC=2140, Recommendation | Experimental | Free SARC, LARC=2140 CFA, Sequential recommendation Receives: Behavioral: Price discounts for SARCs; Behavioral: Price discounts for LARCs |
| Free SARC, LARC=5000, Recommendation | Experimental | Free SARC, LARC=5000 CFA, Sequential recommendation Receives: Behavioral: Price discounts for SARCs |
| Regular SARC, Free LARC, Recommendation | Experimental | Regular price SARC, Free LARC, Sequential recommendation Receives: Behavioral: Price discounts for LARCs |
| Regular SARC, LARC=500, Recommendation | Experimental | Regular price SARC, LARC=500 CFA, Sequential recommendation Receives: Behavioral: Price discounts for LARCs |
| Regular SARC, LARC=1000, Recommendation | Experimental | Regular price SARC, LARC=1000 CFA, Sequential recommendation Receives: Behavioral: Price discounts for LARCs |
| Regular SARC, LARC=2140, Recommendation | Experimental | Regular price SARC, LARC=2140 CFA, Sequential recommendation Receives: Behavioral: Price discounts for LARCs |
| Regular SARC, LARC=5000, Recommendation | No intervention | Regular price SARC, LARC=5000 CFA, Sequential recommendation |
| Free SARC, Free LARC, No Recommendation | Experimental | Free SARC, Free LARC, Simultaneous recommendation Receives: Behavioral: Price discounts for SARCs; Behavioral: Price discounts for LARCs; Behavioral: Sequential vs. simultaneous recommendations |
| Free SARC, LARC=500, No Recommendation | Experimental | Free SARC, LARC=500 CFA, Simultaneous recommendation Receives: Behavioral: Price discounts for SARCs; Behavioral: Price discounts for LARCs; Behavioral: Sequential vs. simultaneous recommendations |
| Free SARC, LARC=1000, No Recommendation | Experimental | Free SARC, LARC=1000 CFA, Simultaneous recommendation Receives: Behavioral: Price discounts for SARCs; Behavioral: Price discounts for LARCs; Behavioral: Sequential vs. simultaneous recommendations |
| Free SARC, LARC=2140, No Recommendation | Experimental | Free SARC, LARC=2140 CFA, Simultaneous recommendation Receives: Behavioral: Price discounts for SARCs; Behavioral: Price discounts for LARCs; Behavioral: Sequential vs. simultaneous recommendations |
| Free SARC, LARC=5000, No Recommendation | Experimental | Free SARC, LARC=5000 CFA, Simultaneous recommendation Receives: Behavioral: Price discounts for SARCs; Behavioral: Sequential vs. simultaneous recommendations |
| Regular SARC, Free LARC, No Recommendation | Experimental | Regular Price SARC, Free LARC, Simultaneous recommendation Receives: Behavioral: Price discounts for LARCs; Behavioral: Sequential vs. simultaneous recommendations |
| Regular SARC, LARC=500, No Recommendation | Experimental | Regular Price SARC, LARC=500 CFA, Simultaneous recommendation Receives: Behavioral: Price discounts for LARCs; Behavioral: Sequential vs. simultaneous recommendations |
| Regular SARC, LARC=1000, No Recommendation | Experimental | Regular Price SARC, LARC=1000 CFA, Simultaneous recommendation Receives: Behavioral: Price discounts for LARCs; Behavioral: Sequential vs. simultaneous recommendations |
| Regular SARC, LARC=2140, No Recommendation | Experimental | Regular Price SARC, LARC=2140 CFA, Simultaneous recommendation Receives: Behavioral: Price discounts for LARCs; Behavioral: Sequential vs. simultaneous recommendations |
| Regular SARC, LARC=5000, No Recommendation | Experimental | Regular Price SARC, LARC=5000 CFA, Simultaneous recommendation Receives: Behavioral: Sequential vs. simultaneous recommendations |
What is being measured
The primary outcome is the main question the study is designed to answer.
The client adopted a LARC
using data from the counseling sessions
Measured: 1-day
The client adopted a modern contraceptive method (LARC or SARC)
using data from the counseling sessions
Measured: 1-day
Secondary outcomes (6)
Was the client treated with respect by the provider during the counseling session?
Self-reported indicator variable using follow-up surveys two weeks after counseling session
Measured: 2-weeks
Did the client trust the provider during the counseling session?
Self-reported indicator variable using follow-up surveys two weeks after counseling session
Measured: 2-weeks
Did the health provider give information about contraceptive methods that was easy to understand during the counseling session?
Self-reported indicator variable using follow-up surveys two weeks after counseling session
Measured: 2-weeks
Client satisfaction with adopted contraceptive method
using 2-week and 16-week follow-up surveys
Measured: 2-week and 16-week measurements
Discontinuation of adopted contraceptive method
using 2-week, 16-week, and 52-week follow-up surveys
Measured: 2-week, 16-week, and 52-week measurements
Percentage of participants with unintended pregnancy within the time frame
using 16-week and 52-week follow-up surveys
Measured: 16-week and 52-week measurements
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Nov 2018
- Study start23 Mar 2021
- Primary completion31 Dec 2022
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ContraceptionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Sequential
- Model description
- The study independently experiments with two aspects of the health provider-client relationship: 1. First, a tablet-based counseling app that is used by the provider gives random discounts to clients - separately for LARCs and SARCs. 2. Second, the tablet-based app presents recommendations to the client sequentially (i.e. the top-ranked method, followed by the next one if that recommendation is declined by the client, etc.) vs. simultaneously (i.e. presenting the top recommendations to the client all at once and asking her to choose which one to discuss further).
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 2,500 participants (actual)
Sponsor and investigators
- Lead sponsor
- World Bank
- Sponsor type
- University, hospital or other
- Collaborators
- Stanford University, George Washington University, University of Exeter, University of California, San Diego, Yaounde Gynecology, Obstetrics and Pediatrics Hospital
- Responsible party
- Principal investigator, Berk Ozler, World Bank
- Investigators
- Berk Ozler, PhD, Principal investigator, World Bank
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03733678
- Sponsor's protocol ID
- LARCs-2018
- Acronym
- HGOPY
- Status last verified
- May 2025
- First submitted
- 31 Oct 2018
- Last updated
- 14 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: We will likely share de-identified anonymous participant data publicly after the trial ends and our analyses are completed.
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Sequential and Adaptive Experiment to Increase the Uptake of Long-acting Reversible Contraceptives in Cameroon
- ClinicalTrials.gov ID
- NCT03733678
- Acronym / sponsor ID
- HGOPY / LARCs-2018
- Conditions
- Contraception, Contraception Behavior, Contraceptive Usage, Contraceptive Method Switching
- Keywords
- adolescent sexual and reproductive health, maternal mortality, teen pregnancy, LARCs, family planning counseling
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 2,500 participants (actual)
- Lead sponsor
- World BankUniversity, hospital or other
- Collaborators
- Stanford University, George Washington University, University of Exeter, University of California, San Diego, Yaounde Gynecology, Obstetrics and Pediatrics Hospital
- Study start
- 23 Mar 2021 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 7 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cameroon exhibits a high and non-decreasing level of maternal mortality (roughly 600 per 100,000 live births), partially related to its relatively high total fertility rate (roughly 4.6). Survey evidence furthermore suggests that a significant fraction of these pregnancies is unwanted or considered mistimed by the mother, especially among females aged 15-19. Despite this, the rate of utilization of family planning (FP) is low: e.g. only 48% of sexually active unmarried women use any form of (modern) contraception, or MC, and even then, it is primarily condoms. The use of LARCs (long-acting reversible contraceptives, i.e. the IUD and implant) is less than 1% according to the most recent Demographic Health Survey.
The study investigators propose to use an integrated behavioral science approach to increase the take-up of both SARCs (short-acting reversible contraceptives, i.e. the pill and injectable) and especially LARCs among reproductive-age females in Cameroon, including adolescents who may be unmarried and/or nulliparous. In addition to decreasing maternal mortality and undesired pregnancies, indirect effects for the community will include: increased welfare from reduced side effects that arise due to current one-size-fits-all FP counseling; healthier children due to improved birth spacing; and increased human capital formation both for children and for young (often school-aged) potential mothers.
The study investigators propose to conduct the study at HGOPY for a duration of 12 months. The study investigators will provide tablets to each of five nurses that conduct FP counseling to participants at the hospital. The tablets contain a counseling "app" (or decision-support tool or a job-aid) that was jointly developed by professionals from HGOPY, the World Bank, and the Ministry of Health. The study investigators propose an individually-randomized experiment, where the participants will be offered randomly varying discounts for the modern contraceptive methods they wish to adopt. The study investigators also propose to experiment with certain aspects of the "app" to improve its effectiveness - both for the participant and for the nurse. More details on the experimental design are provided below.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Single blind (participant)
- Number of arms
- 20
- Model description
- The study independently experiments with two aspects of the health provider-client relationship: 1. First, a tablet-based counseling app that is used by the provider gives random discounts to clients - separately for LARCs and SARCs. 2. Second, the tablet-based app presents recommendations to the client sequentially (i.e. the top-ranked method, followed by the next one if that recommendation is declined by the client, etc.) vs. simultaneously (i.e. presenting the top recommendations to the client all at once and asking her to choose which one to discuss further).
| Arm | Type | Receives |
|---|---|---|
| Free SARC, Free LARC, Recommendation | Experimental | Behavioral: Price discounts for SARCs, Behavioral: Price discounts for LARCsFree SARC, Free LARC, Sequential recommendation |
| Free SARC, LARC=500, Recommendation | Experimental | Behavioral: Price discounts for SARCs, Behavioral: Price discounts for LARCsFree SARC, LARC=500 CFA, Sequential recommendation |
| Free SARC, LARC=1000, Recommendation | Experimental | Behavioral: Price discounts for SARCs, Behavioral: Price discounts for LARCsFree SARC, LARC=1000 CFA, Sequential recommendation |
| Free SARC, LARC=2140, Recommendation | Experimental | Behavioral: Price discounts for SARCs, Behavioral: Price discounts for LARCsFree SARC, LARC=2140 CFA, Sequential recommendation |
| Free SARC, LARC=5000, Recommendation | Experimental | Behavioral: Price discounts for SARCsFree SARC, LARC=5000 CFA, Sequential recommendation |
| Regular SARC, Free LARC, Recommendation | Experimental | Behavioral: Price discounts for LARCsRegular price SARC, Free LARC, Sequential recommendation |
| Regular SARC, LARC=500, Recommendation | Experimental | Behavioral: Price discounts for LARCsRegular price SARC, LARC=500 CFA, Sequential recommendation |
| Regular SARC, LARC=1000, Recommendation | Experimental | Behavioral: Price discounts for LARCsRegular price SARC, LARC=1000 CFA, Sequential recommendation |
| Regular SARC, LARC=2140, Recommendation | Experimental | Behavioral: Price discounts for LARCsRegular price SARC, LARC=2140 CFA, Sequential recommendation |
| Regular SARC, LARC=5000, Recommendation | No intervention | –Regular price SARC, LARC=5000 CFA, Sequential recommendation |
| Free SARC, Free LARC, No Recommendation | Experimental | Behavioral: Price discounts for SARCs, Behavioral: Price discounts for LARCs, Behavioral: Sequential vs. simultaneous recommendationsFree SARC, Free LARC, Simultaneous recommendation |
| Free SARC, LARC=500, No Recommendation | Experimental | Behavioral: Price discounts for SARCs, Behavioral: Price discounts for LARCs, Behavioral: Sequential vs. simultaneous recommendationsFree SARC, LARC=500 CFA, Simultaneous recommendation |
| Free SARC, LARC=1000, No Recommendation | Experimental | Behavioral: Price discounts for SARCs, Behavioral: Price discounts for LARCs, Behavioral: Sequential vs. simultaneous recommendationsFree SARC, LARC=1000 CFA, Simultaneous recommendation |
| Free SARC, LARC=2140, No Recommendation | Experimental | Behavioral: Price discounts for SARCs, Behavioral: Price discounts for LARCs, Behavioral: Sequential vs. simultaneous recommendationsFree SARC, LARC=2140 CFA, Simultaneous recommendation |
| Free SARC, LARC=5000, No Recommendation | Experimental | Behavioral: Price discounts for SARCs, Behavioral: Sequential vs. simultaneous recommendationsFree SARC, LARC=5000 CFA, Simultaneous recommendation |
| Regular SARC, Free LARC, No Recommendation | Experimental | Behavioral: Price discounts for LARCs, Behavioral: Sequential vs. simultaneous recommendationsRegular Price SARC, Free LARC, Simultaneous recommendation |
| Regular SARC, LARC=500, No Recommendation | Experimental | Behavioral: Price discounts for LARCs, Behavioral: Sequential vs. simultaneous recommendationsRegular Price SARC, LARC=500 CFA, Simultaneous recommendation |
| Regular SARC, LARC=1000, No Recommendation | Experimental | Behavioral: Price discounts for LARCs, Behavioral: Sequential vs. simultaneous recommendationsRegular Price SARC, LARC=1000 CFA, Simultaneous recommendation |
| Regular SARC, LARC=2140, No Recommendation | Experimental | Behavioral: Price discounts for LARCs, Behavioral: Sequential vs. simultaneous recommendationsRegular Price SARC, LARC=2140 CFA, Simultaneous recommendation |
| Regular SARC, LARC=5000, No Recommendation | Experimental | Behavioral: Sequential vs. simultaneous recommendationsRegular Price SARC, LARC=5000 CFA, Simultaneous recommendation |
Who may qualify
- Ages
- 10 to 49 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (4 listed)
- Female
- Ages 10-49
- Presenting at HGOPY seeking FP counseling/services
- HGOPY clients referred to the family planning unit for consultation
Key exclusion criteria (1 listed)
- No exclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Price discounts for SARCsSARCs are offered free to the client | Behavioural | Free SARC, Free LARC, No Recommendation, Free SARC, Free LARC, Recommendation, Free SARC, LARC=1000, No Recommendation, Free SARC, LARC=1000, Recommendation, Free SARC, LARC=2140, No Recommendation, Free SARC, LARC=2140, Recommendation, Free SARC, LARC=500, No Recommendation, Free SARC, LARC=500, Recommendation, Free SARC, LARC=5000, No Recommendation, Free SARC, LARC=5000, Recommendation |
| Price discounts for LARCsLARCs are offered at lower prices to the client | Behavioural | Free SARC, Free LARC, No Recommendation, Free SARC, Free LARC, Recommendation, Free SARC, LARC=1000, No Recommendation, Free SARC, LARC=1000, Recommendation, Free SARC, LARC=2140, No Recommendation, Free SARC, LARC=2140, Recommendation, Free SARC, LARC=500, No Recommendation, Free SARC, LARC=500, Recommendation, Regular SARC, Free LARC, No Recommendation, Regular SARC, Free LARC, Recommendation, Regular SARC, LARC=1000, No Recommendation, Regular SARC, LARC=1000, Recommendation, Regular SARC, LARC=2140, No Recommendation, Regular SARC, LARC=2140, Recommendation, Regular SARC, LARC=500, No Recommendation, Regular SARC, LARC=500, Recommendation |
| Sequential vs. simultaneous recommendationsTop ranked methods are presented to the client sequentially or simultaneously | Behavioural | Free SARC, Free LARC, No Recommendation, Free SARC, LARC=1000, No Recommendation, Free SARC, LARC=2140, No Recommendation, Free SARC, LARC=500, No Recommendation, Free SARC, LARC=5000, No Recommendation, Regular SARC, Free LARC, No Recommendation, Regular SARC, LARC=1000, No Recommendation, Regular SARC, LARC=2140, No Recommendation, Regular SARC, LARC=500, No Recommendation, Regular SARC, LARC=5000, No Recommendation |
Primary outcome
The client adopted a LARC
Time frame: 1-day
using data from the counseling sessions
The client adopted a modern contraceptive method (LARC or SARC)
Time frame: 1-day
using data from the counseling sessions
6 secondary outcomes
Was the client treated with respect by the provider during the counseling session?
Time frame: 2-weeks
Did the client trust the provider during the counseling session?
Time frame: 2-weeks
Did the health provider give information about contraceptive methods that was easy to understand during the counseling session?
Time frame: 2-weeks
Client satisfaction with adopted contraceptive method
Time frame: 2-week and 16-week measurements
Discontinuation of adopted contraceptive method
Time frame: 2-week, 16-week, and 52-week measurements
Percentage of participants with unintended pregnancy within the time frame
Time frame: 16-week and 52-week measurements
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2025.
- Individual participant dataSharing planned: Undecided. We will likely share de-identified anonymous participant data publicly after the trial ends and our analyses are completed.
Related trials for Contraception
Enrolling by invitation
Flo Digital Contraceptive Study
Contraception Use
Recruiting
Estimating the Impact of Sexuality Education and Mobile Health Services on Reproductive Health and Empowerment Among Adolescents in Sierra Leone for the Family Planning Impact Lab
Reproductive Health, Sexual Health
RecruitingPhase 4
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Not yet recruitingObservational study
FLOW: Influence of the Menstrual Cycle on Alcohol Use in Women
Alcohol Use, Alcohol Consumption
Not yet recruiting
Impact of Gender-Transformative Interventions on Contraceptive Use and Reproductive Autonomy in Somalia
Contraceptive Behavior, Social Norms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Berk Ozler, PhD principal investigator
World Bank
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Price discounts for SARCs, Price discounts for LARCs and Sequential vs. simultaneous recommendations in people with Contraception and Contraception Behavior, run by World Bank at 1 site in Cameroon.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Cameroon. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The client adopted a LARC (time frame: 1-day). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2025.